Pharmacological optimization of regenerative medicine and transplantation procedures and outcomes - QC-494

Project type: Research
Desired discipline(s): Engineering - other, Engineering, Biochemistry / Molecular biology, Life Sciences, Biology, Medicine, Pharmacy / Pharmacology
Company: Targa Biomedical
Project Length: Longer than 1 year
Preferred start date: 01/01/2022
Language requirement: Flexible
Location(s): Montreal, QC, Canada; Canada
No. of positions: 2
Desired education level: PhDPostdoctoral fellow
Search across Mitacs’ international networks - check this box if you’d also like to receive profiles of researchers based outside of Canada: 
No

About the company: 

Targa Biomedical develops pharmacological treatments that enhance the quality and therapeutic impact of cell therapy / regenerative medicine and increase opportunities for organ transplantation. Targa's drug discovery and development platform have advanced small molecules integrating into in vitro cell manufacturing processes in order to increase viable cellular yields, and into ex vivo preservation / perfusion protocols to rescue marginal quality organs and improve clinical outcomes of transplantation. Targa is also leading the world’s first pharmacologically optimized CD133+ cell transplantation protocol for ischemic cardiomyopathy treatment. Targa’s pipeline showcases two products in advanced development stage.

TBM005/72A: Added to preservation, perfusion, or culture solutions, this ancillary product enhances manufactured cell viability, functionality, and therapeutic efficacy for a wide variety of cells including stem cells and differentiated cells, from autologous and allogeneic sources. This product is directed towards the cell therapy / regenerative medicine market to support the ever-growing pipelines of global cell and gene therapy companies.

TBM005/7: Added to ex vivo reconditioning solutions, this pharmacological product reconditions marginal quality tissues including Donation after Cardiocirculatory Death (DCD) organs (lung, heart, liver) thereby increasing opportunities for life-saving transplantations. This product is directed towards the ex vivo preservation / perfusion market expected to revolutionize transplantation programs.

Describe the project.: 

The project involves testing and development of novel molecules used to improve cell and organ function for the clinical optimization of regenerative medicine and transplantation outcomes. Two categories of conditioning treatments are evaluated including a stem cell ‘pharmaco-optimization’ product capable of increasing cell manufacturing quality, as well as cell viability, retention, and therapeutic effectiveness for regenerative medicine protocols. The second category of treatment evaluated is an organ ‘re/conditioning’ product capable of rescuing marginal quality lungs, hearts, and livers and ensuring protection from ischemia or inflammation.

To further these goals, Targa Biomedical is seeking enthusiastic scientists interested in contributing to the development of next-generation technologies in regenerative medicine and transplantation. The successful candidate will contribute to a translational research program and will work within a multidisciplinary team composed of researchers, physicians, and industrial partners. This is intended to be a growth position geared primarily towards candidates interested in a university-industry transition path.

Responsibilities include:

  • Design and execute laboratory experiments
  • Contribute to the collaborative research efforts both within the lab and with collaborators
  • Communicate scientific discoveries through peer-reviewed publications and presentations
  • Contribute in grant writing
  • Work closely with the research and medical teams and with the startup company
  • Participate in weekly group meetings

Required expertise/skills: 

Qualifications:

  • Completed, within the last 3 years, a relevant Ph.D. in molecular biology, biomedical sciences, pharmacology, regenerative medicine, or a related discipline
  • Highly motivated, organized, and independent learner that can adapt quickly to a multidisciplinary environment composed of researchers, physicians, and industrial partners 
  • Thrive in a teamwork environment and assume team-building role for newer recruits (interns and graduate students)
  • Good communicator with solid publication and presentation track record
  • Familiar with cell culture techniques, immunocytochemistry, confocal imaging, qPCR, manipulation of tissues and laboratory animals

Ideally, additional expertise in:

  • Stem cells, regenerative medicine, organ transplantation
  • Advanced cell-culture and tissue engineering techniques
  • Experience in project management is desirable